Atopic dermatitis new drug CCR4 inhibitor phase Ib results positive company share price doubles

Article source: Medical Rubik's Cube Info

On June 14, RAPT Therapeutics announced that a randomized, placebo-controlled phase Ib clinical trial of RPT193 monotherapy in 31 patients with moderate to severe atopic dermatitis has achieved positive top-line results

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by damage to the skin barrier and immune disorders, which can lead to skin damage and itching in patients, which seriously affects the quality of life

RPT193 is a small molecule oral CC chemokine receptor 4 (CCR4) antagonist, which can selectively inhibit the migration of Th2 cells to inflammatory tissues by blocking the highly expressed CCR4 receptor on Th2 cells

This phase Ib trial aims to explore the efficacy and safety of RPT193 in patients with moderate to severe atopic dermatitis.

The results of the study showed that after 4 weeks of treatment, the eczema area and severity index (EASI) score of moderate to severe AD patients in the RPT193 group improved by 36.

On day 43, 14.

On day 29, patients in the RPT193 group had a clinically significant improvement in pruritus symptoms compared with the placebo group

In terms of safety, PT193 was well tolerated in the phase Ib study

According to the comparison of existing clinical data of other products, the efficacy data of RPT193 in the treatment of AD for 4 weeks is equivalent to the efficacy of anti-IL-4Rα monoclonal antibody du Priyuumab and Pfizer JAK1 inhibitor abrocitinib for 12-16 weeks

Based on the efficacy and safety data observed in the phase Ib study, RAPT plans to initiate a phase IIb study for patients with moderate to severe AD, and plans to conduct a phase IIa study for asthma